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Abstract
Background. Little is known about the decline of kidney
function in patients with normal kidney function at base-
line. Our objectives were to (i) identify predictors of inci-
dent chronic kidney disease (CKD) and (ii) to estimate rate
of decline in kidney function.
Methods. The study used a retrospective cohort of adult
patients in a hypertension registry in an inner-city health
care delivery system in Denver, Colorado. The primary
outcome was development of incident CKD, and the sec-
ondary outcome was rate of change of estimated glomeru-
lar filtration rate (eGFR) over time.
Results. After a mean follow-up of 45 months, 429 (4.1%)
of 10 420 patients with hypertension developed CKD. In
multivariate models, factors that independently predicted
incident CKD were baseline age [odds ratio (OR) 1.13
per 10 years, 95% confidence interval (CI), 1.03–1.24],
baseline eGFR (OR 0.69 per 10 units, 95% CI 0.65–
0.73), diabetes (OR 3.66, 95% CI 2.97–4.51) and vascular
disease (OR 1.67, 95% CI 1.32–2.10). We found no inde-
pendent association between age, gender or race/ethnicity
and eGFR slope. In patients who did not have diabetes or
vascular disease, eGFR declined at 1.5 mL/min/1.73 m
2
per year. Diabetes at baseline was associated with an addi-
tional decline of 1.38 mL/min/1.73 m
2.
Conclusions. Diabetes was the strongest predictor of both
incident CKD as well as eGFR slope. Rates of incident
CKD or in decline of kidney function did not differ by race
or ethnicity in this cohort.
Keywords: chronic kidney disease; hypertension; progression
Introduction
Chronic kidney disease (CKD) is common, affecting
13.1% of the United States (US) population; 26.3 million
Americans are estimated to have stages 1–4 CKD [1]. Hy-
pertension is closely associated with CKD; 70% of patients
with an elevated serum creatinine (defined as ≥1.6 mg/dL
for men and ≥1.4 mg/dL for women) have hypertension
[2], and 26.8% of patients with end-stage renal disease
(ESRD) were deemed to have kidney failure as a result
of hypertension by treating nephrologists [3]. Although
high blood pressure is a major promoter of the decline in
glomerular filtration rate (GFR) in diabetic and non-dia-
betic kidney disease [4], only a small percentage of pa-
tients with hypertension will develop CKD [5]. Therefore
being able to identify those hypertensive individuals at
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of their disease process may help to guide their treatment.
Existing studies on the rate of decline in kidney function
have been based on subjects in whom CKD (defined as
GFR <60 mL/min/1.73 m
2) has already developed; little
information is available on rates of decline in kidney func-
tion prior to the onset of CKD [6], specifically in known
hypertensive cohorts. In addition, many inferences have
been drawn from post-hoc analyses of subjects enrolled
in clinical trials, who may not be representative of patients
encountered in routine clinical care.
Therefore, the objectives of the current study were to (i)
identify predictors of incident CKD and (ii) to estimate
rate of decline in kidney function in a racially and ethni-
cally diverse hypertensive patient population with normal
or near normal kidney function at baseline.
Methods
Subjects
The data source for the study was an electronic registry of patients with
hypertension atDenver Health,alargesafety-netcommunityhealthsystem
inDenver,Colorado,USAwhichprovidesintegratedprimary andspecialty
care and emergency medicine and acute hospital care for the socially dis-
advantaged, vulnerable population of Denver [7,8]. The registry assembled
information from patient registration files (age, sex, race/ethnicity, marital
statusand language), claims files (site, date, payerand diagnostic codes for
all visits), laboratory files (dates and results of blood and urine tests) and
pharmacy files. Patients were included in the registry if they received care
between 1 January 2000 and 31 December 2006 and had at least one ICD-
9CM(InternationalClassificationofDiseases,9thRevision,ClinicalMod-
ification) code for hypertension (401, 401.0, 401.1, 401.9, 405, 405.0,
405.01, 405.09, 405.1, 405.11, 405.19, 405.9, 405.91, 405.99, 642.0x,
642.1x, 642.2x, 642.3x, 642.4x, 642.5x, 642.6x, 642.7x, 642.9x) coded
ineitheraninpatientoroutpatientadministrativeclaim.Wehavepreviously
found that this method for identifying patients with hypertension (defined
as blood pressure >130/80 mm Hg in diabetic patients or >140/90 mm Hg
in patients without diabetes) has a sensitivity of 88% and a specificity of
78% [9]. For the current analysis, we excluded patients with missing infor-
mation on gender, individuals with no contact with the Denver Health sys-
tem after their hypertension diagnosis, individuals who were <21 years of
age at the time of first visit for hypertension and individuals who received
pregnancy-related care during the study time period (because of known
physiologic changes in the serum creatinine during pregnancy). We also
excluded patients with a baseline estimated glomerular filtration rate
(eGFR) <60 or >200 mL/min/1.73 m
2 or who did not have two baseline
eGFR values ≥ 60 mL/min/1.73 m
2 at least 1 month apart using the Mod-
ificationofDietinRenalDiseases(MDRD)predictionequation[10].Thus,
patients included in this analysis were required to have a minimum of three
serum creatinine measurements for inclusion, the first two to establish the
baseline eGFR and the third, at least 1 year after the index date in order to
calculate the rate of change of eGFR over time.
Definitions
The index date for the study cohort was defined as the time of the first
creatinine measurement after entry into the hypertension registry. We de-
fined baseline comorbidities (diabetes, vascular disease, congestive heart
failure, dyslipidemia, mental health conditions and substance abuse) using
combinations of billing codes and laboratory values as previously de-
scribed [9]. We defined vascular disease as a composite including coro-
nary heart disease, peripheral vascular disease and cerebrovascular
disease. The mental health diagnosis was comprised of individuals with
depression, bipolar disorder and psychotic conditions. The substance
abuse diagnosis combined alcohol dependence with illicit drug use or de-
pendence. These comorbidities were counted as present at baseline if they
were first recorded on visits prior to or up to 180 days after the index date.
Estimated GFR was defined using the four-variable abbreviated MDRD
study equation: eGFR = 186 × [serum creatinine (mg/dL)]
−1.154 ×
[age]
−0.203 × [0.742 if female] × [1.210 if black] [10]. As only 37% of
our study population had a payer source which would require them to fill
their medications within the Denver Health system, we did not include
concurrent prescribed medications in this analysis.
All creatinine measurements were performed on a Roche Hitachi Mod-
ular Analytics P model analyzer (Roche Diagnostics, Indianapolis, IN,
USA) by the modified Jaffe reaction and were calibrated to the isotope
dilution mass spectrometry (IDMS) traceable creatinine standard. All
available creatinine measurements (both inpatient and outpatient) were in-
cluded in the analysis. A second analysis including only creatinine mea-
surements from outpatient visits was performed which demonstrated
similar associations and is not reported here.
The primary outcome of interest, incident CKD, was defined using the
National Kidney Foundation Disease Outcome Quality Initiative (NKF/
DOQI) definition of eGFR <60 mL/min/1.73 m
2 persisting for at least
3 months [10]. We operationalized this definition as a final eGFR <60
mL/min/1.73 m
2 with at least one other eGFR 3 months prior <60 mL/
min/1.73 m
2 and no intervening eGFR measurements ≥ 60 mL/min/1.73
m
2. The secondary outcome was the rate of change in eGFR per 6-month
time interval, defined as slope of the linear relationship between eGFR
and time.
Statistical analyses
We compared baseline characteristics of those who developed CKD to
those who did not using t tests or Wilcoxon rank sum tests for continuous
variables and chi-square or Fisher exact tests for dichotomous or categor-
ical predictors. We used stepwise multivariable logistic regression analysis
to identify predictors of the primary outcome (development of incident
CKD). Logistic regression was chosen over a Cox model due to (i) high
variability of the timing and number of creatinine measurements for each
patient and (ii) exact timing that participants reached the renal endpoint of
CKD could not be established. Covariates were considered candidates for
inclusion in the model if the P value on bivariate testing was <0.25. To
derive the final model, variables were excluded using backwards elimina-
tion until all P values were <0.25. Model discrimination was assessed
with the c-statistic, and model calibration was assessed with the Hos-
mer–Lemeshow statistic.
Weusedgenerallinearmixed-effectsmodels(randomslopeandrandom
intercept) to estimate the rate of decline in eGFR and the degree to which
the baseline covariates predicted eGFR. Prior to calculating eGFR, all cre-
atininemeasurementsineach6-monthblockwereaveragedtosmoothhigh
within-patient variability [11]. Non-physiologic eGFR values of >200 mL/
min/1.73 m
2 were set to a maximum value of 200 mL/min/1.73 m
2 for
eGFR values after the baseline measurements for analyses examining rate
of decline in eGFR[12]. Repeatedmeasureswithin eachpatient were mod-
eled as a linear time trend (growth curve) model. Time was coded into 6-
monthperiodsafterbaseline(e.g.ifeGFRbasedonmeanofcreatininemea-
surements within the first 6 months, time = 0; if eGFR based on mean of
creatinine measurements from 6 to 12 months, time = 1, etc.). All analyses
were conducted with SAS Version 9.1 (SAS Institute, Cary, NC, USA).
Results
After excluding patients with <3 creatinine measurements,
those with CKD at baseline or those who were in an inde-
terminate category (did not have both of their baseline
eGFR measurements ≥60 mL/min/1.73 m
2) (Figure 1), a
total of 10 420 patients with hypertension met our inclusion
criteria. These individuals had a total of 134 983 creatinine
measurements with a median of eight measurements [inter-
quartile range (IQR) 5–15] and with a mean period of ob-
servation of 3.73 years (range 1–6.94 years). For the rate of
change analysis, after averaging the creatinine values in 6-
month time intervals, the median number of measurements
per patient was 5 (interquartile range 3–7) (data not shown).
The mean time in the hypertension registry was 62.4
months, and the mean duration of follow-up after the first
creatinine measurement was 44.7 months. We had self-re-
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ported a median income of $7680 (IQR $4164–$12 992).
Baseline characteristics of the whole cohort are shown in
Table 1.
As shown in Table 2, 429 patients (4.1% of the study co-
hort) developed CKD. The results of the logistic regression
for risk of incident CKD are shown in Table 3. Age (OR
1.13 per 10 years, 95% CI 1.03–1.24), baseline eGFR
(0.69 per 10 units, 0.65–0.73), presence of diabetes (3.66,
2.97–4.51) and vascular disease (1.67, 1.32–2.10) indepen-
dently predicted incident CKD (Table 3). The c-statistic for
this model was 0.81, indicating good discrimination. Race
and ethnicity were not independent predictors of incident
CKD in this cohort. In order to test whether therewas a sys-
tematic difference in patients who had insufficient creati-
nine measurements to meet the incident CKD definition,
we performed a sensitivity analysis, requiring just a single
finaleGFR<60mL/min/1.73m
2todefineincidentCKD.In
this analysis, the incidence ofCKD was higher (10.2%), but
therewasnosignificantdifference inanyoftheassociations
in bivariate or multivariate testing.
Predictors of eGFR at baseline and of the change of
eGFR over time are shown in Table 4. The intercept values
represent the within sub-group difference in baseline
eGFR. The slope values represent the rate of change of
eGFR over a 6 month time interval, where a negative num-
ber represents a decline in kidney function. African Amer-
ican race, Hispanic ethnicity and presence of diabetes were
associated with higher eGFR at baseline. Older age and fe-
male sex were associated with lower eGFR at baseline.
However, none of these factors was independently associ-
ated with the eGFR slope.
Figures 2 and 3 represent model-based estimates of the
eGFR slopes, created by using the intercepts, slopes and
duration of observation from the models to construct the
graphs. For patients who did not have diabetes or vascular
disease at baseline, an eGFR decline of 1.52 mL/min/1.73
m
2 per year was observed (Figure 2). Presence of diabetes
at baseline was associated with an additional decline of
1.38 mL/min/1.73 m
2 per year, resulting in an overall de-
cline of 2.9 mL/min/1.73 m
2 per year. Although the pres-
ence of vascular disease alone at baseline was not
significantly associated with a worsening decline in eGFR,
the combination of both diabetes and vascular disease re-
sulted in an additional decline of 0.62 mL/min/1.73 m
2 per
year with an overall decline of 3.52 mL/min/1.73 m
2 per
year (Figure 3).
In an attempt to assess the impact of blood pressure con-
trol on our findings, we conducted a secondary analysis in
the 528 individuals (5.1% of the original cohort) who had
blood pressure readings at the time of their entry into the
cohort. In this small sub-group, baseline systolic blood
Fig. 1. Eligibility for incident CKD and GFR progression cohorts among
patients included in the hypertension registry.
Table 1. Baseline characteristics
Total
n = 10420
n (%)
Age, years 55.0 (11.9)
Male sex 4672 (44.8%)
Race/ethnicity 2805 (26.9%)
African American 4556 (43.7%)
Hispanic 2722 (26.1%)
White 209 (2.0%)
Other 128 (1.2%)
Missing
Marital status 3224 (30.9%)
Married 6467 (62.1%)
Other 729 (7.0%)
Unknown
Language 7157 (68.7%)
English 1785 (17.1%)
Spanish 384 (3.7%)
Other 1094 (10.5%)
Missing
Duration in hypertension registry, months 62.4 (19.2)
Period of observation, months 44.7 (20.1)
Comorbidities
Diabetes 3822 (36.7%)
Vascular 1721 (16.5%)
Congestive heart failure 37 (0.4%)
Dyslipidemia 1766 (17.0%)
Mental health 2614 (25.1%)
Substance abuse 1666 (16.0%)
Baseline eGFR (mL/min/1.73 m
2) 98.7 (23.6)
Data are presented as mean (SD) or n (%). eGFR = estimated glomerular
filtration rate.
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cident CKD. However, each increase of 10 mm Hg in sys-
tolic blood pressure resulted in a decline of 0.29 mL/min/
1.73 m
2 in eGFR per 6-month period (P = 0.09). Inclusion
of blood pressure in the multivariate models did not alter
the findings of the main analysis.
Table 3. Multivariate analysis of predictors of incident CKD
Unadjusted OR Adjusted OR Adjusted
(95% CI) (95% CI) P value
Age at time zero (per 10 years) 1.42 (1.31–1.53) 1.13 (1.03–1.24) 0.008
Gender Ref.
Male 1.36 (1.11–1.66)
Female
Race/ethnicity 1.20 (0.90–1.59)
African American 1.51 (1.17–1.94)
Hispanic Ref.
White 0.91 (0.47–1.76)
Other/missing
Duration of hypertension, per year 1.37 (1.27–1.47)
Period of observation, per 6 months 1.23 (1.19–1.27) 1.21 (1.17–1.25) <0.0001
Baseline eGFR**, per 10 units 0.67 (0.64–0.72) 0.69 (0.65–0.73) <0.0001
Comorbidities
Diabetes 3.53 (2.88–4.33) 3.66 (2.97–4.51) <0.0001
Vascular 1.91 (1.53–2.38) 1.67 (1.32–2.10) <0.0001
Congestive heart failure 2.06 (0.63–6.74)
Mental health 0.64 (0.50–0.83)
Substance abuse 0.57 (0.42–0.79)
OR = odds ratio; CI = confidence interval; eGFR = estimated glomerular filtration rate. c-statistic: 0.81. Hosmer–Lemeshow Goodness-of-Fit Test:
P = 0.01.
**Baseline eGFR is the first measured eGFR after the diagnosis of hypertension.
Table 2. Bivariate associations of baseline characteristics with incident CKD
No CKD Incident CKD
P value
n = 9991 (95.9%) n = 429 (4.1%)
n (%) n (%)
Age at time zero, years 54.8 (11.8)/54.3 59.8 (11.0) <0.0001
Male sex 4510 (45.1%) 162 (37.8%) 0.003
Race/ethnicity 2696 (27.0%) 109 (25.4%)
African American 4335 (43.4%) 221 (51.5%)
Hispanic 2633 (26.4%) 89 (20.8%)
White 201 (2.0%) 8 (1.9%)
Other 126 (1.3%) 2 (0.5%) 0.008
Missing
Marital status 3081 (30.8%) 143 (33.3%)
Married 6208 (62.1%) 259 (60.4%)
Other 702 (7.0%) 27 (6.3%) 0.51
Unknown
Language 6866 (68.7%) 291 (67.8%)
English 1707 (17.1%) 78 (18.2%)
Spanish 367 (3.7%) 17 (4.0%)
Other 1051 (10.5%) 43 (10.0%) 0.91
Missing
Duration in hypertension registry, months 61.2 (19.2) 69.6 (16.8) <0.0001
Period of observation, months 44.1 (20.0) 57.2 (18.6) <0.0001
Comorbidities
Diabetes 3539 (35.4%) 283 (66.0%) <0.0001
Vascular 1606 (16.1%) 115 (26.8%) <0.0001
Congestive heart failure 34 (0.3%) 3 (0.7%) 0.19
Dyslipidemia 1685 (16.9%) 81 (18.9%) 0.28
Mental health 2537 (25.4%) 77 (18.0%) 0.0005
Substance abuse 1623 (16.2%) 43 (10.0%) 0.0006
Baseline eGFR (mL/min/1.73 m
2) 99.3 (23.5) 84.2 (20.2) <0.0001
Data are presented as mean (SD) or n (%). eGFR = estimated glomerular filtration rate; CKD = chronic kidney disease.
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Within a large community-based, racially and ethnically
diverse sample of hypertensive patients with normal or
near normal kidney function at baseline, diabetes was the
strongest predictor of incident CKD and resulted in a more
rapid decline in kidney function than in non-diabetics. In
addition, the combination of diabetes and vascular disease
at baseline was associated with even more rapid decline in
eGFR than diabetes alone. Contrary to previous literature,
we did not find differences in rate of decline in kidney
function by race and ethnicity in a group of diverse patients
with similar access to care and socioeconomic status.
In the current study, the rate of decline of kidney func-
tion in patients without diabetes or vascular disease at base-
line was greater than the expected 1 mL/min/1.73 m
2 that is
widely considered to be the “normal” decline in kidney
function with age [10]. This decline is also greater than
what was found in the Baltimore Longitudinal Study of
Aging [6] (0.75 mL/min/year) in a European study of pa-
tients with existing CKD (1.03 mL/min/1.73 m
2 per year)
[13] and an elderly Canadian community-based cohort
with CKD at baseline (0.8 mL/min/1.73 m
2 for females
and 1.4 mL/min/1.73 m
2 per year decline for males)
[14]. However, slopes for diabetic patients were similar
in our study to the slopes reported by Hemmelgarn and
colleagues (2.9 mL/min/1.73 m
2 vs. 2.7 mL/min/1.73 m
2
per year, respectively) [14]. It is conceivable that the
apparent discrepant results among the published studies
[6,13,14] and our analysis are due to the fact that the
patients included in this cohort were all hypertensive, had
a higher burden of comorbidities and were of a lower
socioeconomic status.
Two prior studies have assessed predictors of incident
CKD. In an analysis of the Atherosclerosis Risk in Com-
munities (ARIC) and the Cardiovascular Health Study
(CHS) datasets, Kshirsagar et al. developed a prediction
rule to predict incident CKD [15]. Contrary to our results,
these investigators found white race to be associated with
incident CKD. Other independent predictors of CKD in
this study included age, female sex, diabetes, hyperten-
sion, cardiovascular disease, peripheral vascular disease,
anemia, congestive heart failure and low high-density lipo-
protein. This analysis was limited by (i) a shorter follow-up
of the African American sub-group, (ii) using only a single
eGFR <60 mL/min/1.73 m
2 to define incident CKD and
(iii) failure to perform analysis on eGFR decline.
Fox et al. assessed a subset of the Framingham cohort
with normal kidney function at baseline that attended two
examinations 10 years apart [16]. Their primary outcome
was development of CKD defined as a single eGFR
<59.25 mL/min/1.72 m
2 for women and 64.25 mL/min/
1.72 m
2 for men. In their multivariate model, they found
age, presence of diabetes, BMI (body mass index), smok-
ing, baseline eGFR and male sex to be associated with in-
cident CKD. The study population was predominantly
white, so they were unable to assess the effect of race/eth-
nicity on the development of CKD.
Table 4. Coefficients of the intercepts and slopes of eGFR progression
analysis
Variables Intercept coefficient (SE) P value
Variables that affect the intercept
Intercept
a 96.17 (.47) <0.0001
Race/ethnicity <0.0001
African American 4.05 (.54)
Latino 2.96 (.49)
Other race −1.65 (1.15)
Female gender −2.73 (.40) <0.0001
Age at baseline −.58 (.02) <0.0001
Diabetes 1.68 (.47) 0.0004
Vascular disease .10 (.72) 0.89
Diabetes × vascular disease −1.65 (1.11) 0.14
Variables that affect slope Slope coefficient
b (SE) P value
Time
c −.76 (.04) <.0001
Time × diabetes −.69 (.06) <0.0001
Time × vascular disease −.09 (.10) 0.3556
Time × diabetes × vascular disease −.31 (.16) 0.0464
aeGFR at baseline when covariates = 0 (e.g. white, male, age 55, no di-
abetes or vascular disease).
bChange in eGFR per 6 months.
cSlope at baseline when covariates = 0 (e.g. white, male, age 55, no dia-
betes or vascular disease).
Fig. 2. eGFR change over time in patients without diabetes or vascular
disease.
Fig. 3. eGFR progression for reference group (no diabetes or vascular
disease), presence of diabetes, vascular disease, and both diabetes and
vascular disease.
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times greater than non-Hispanic whites [3] although their
prevalence of CKD in the USA is similar [1,17]. This dis-
crepancy has been attributed to a faster decline in kidney
function in African Americans with existing kidney dis-
ease [17]. Furthermore, Latino individuals represent the
largest minority group in the USA and have 1.5 times
higher rates of incident ESRD than non-Hispanic whites.
However, data on rates of progression in this group are
scarce [18]. To our knowledge, this is the first study to
look at rate of decline of eGFR over time in a hypertensive,
racially and ethnically diverse community-based sample
with normal or near normal kidney function at baseline.
Our findings that race or ethnicity is not associated with
incident CKD or decline of eGFR from normal kidney
function suggest that the increased incidence of ESRD ob-
served in these populations is due to factors that occur after
the onset of CKD. In this regard, Hsu et al. demonstrated
that the incidence of CKD was not higher in African
Americans when compared to whites but that African
Americans with CKD presumably progressed to ESRD at
five times the rate of whites with CKD [17]. Peralta et al.
demonstrated that Latinos with CKD had nearly a 2-fold
risk of developing ESRD when compared to whites with
CKD [18]. Finally, differences observed between studies
may not account for important differences in access to
health care, the quality of care for individuals with hyper-
tension or for important comorbid health conditions such
as diabetes or vascular disease, which may accelerate the
decline in kidney function.
An important strength of our study was our inclusion of
all three major racial/ethnic groups in the USA. Another
advantage of our study was the requirement that the devel-
opment of CKD be persistent for at least 3 months (NKF/
DOQI definition of CKD). In addition, we included an as-
sessment of the rate of decline of eGFR that has not been
previously reported for individuals with normal kidney
function at baseline. Thus, assessing progression by rate
of change of eGFR over time allows for more complete
assessment of the risk factors for progression [19], not just
those who achieve the dichotomous primary outcome of
incident CKD.
This study has a number of limitations. First, we relied
on estimating GFR from the MDRD study equation rather
than using a direct method of measuring the GFR. Our
study relied on laboratory values measured in routine clin-
ical care so that a direct measure of GFR (mGFR) was not
possible. In addition, the MDRD study equation does not
perform as well at higher levels of GFR [20] and may have
resulted in inaccuracy in classifying patients. Despite these
concerns, the MDRD estimating equation is recommended
for use by the NKF/DOQI guidelines and is the most wide-
ly used prediction equation in clinical practice. In addition,
because estimating equations are derived from cross sec-
tional data, there is some concern about the ability of es-
timating equations to assess changes in GFR over time.
Xie et al. evaluated the performance of the MDRD study
equation to assess eGFR slope when compared to a direct
mGFR. They found that the MDRD eGFR underestimated
the slope decline by 28%, but none of the tested clinical
variables predicted a systematic difference between mGFR
and eGFR slope [21]. Therefore, using the MDRD equa-
tion may have led us to underestimate the eGFR slope, but
it was unlikely to affect the predictors associated with
more rapid decline in GFR.
Second, the use of creatinine values measured in routine
clinical care can result in systematic bias. Patients with
more comorbidities are more likely to be engaged in the
medical system and may have more frequent laboratory
monitoring than their healthier counterparts. In addition,
patients who were demonstrating a decline in kidney func-
tion may have received more measurements of serum cre-
atinine. Third, we were unable to assess the severity of
hypertension in our patients in our registry due to incom-
plete pharmacy data and limited blood pressure data. Other
limitations include inability to control for use of antihyper-
tensive medications, variability of duration of follow-up
within the cohort and restriction of our analysis to patients
with hypertension which did not allow assessment of the
impact of hypertension on the development of incident
CKD as we did not have a comparator group without hy-
pertension. It also likely led to estimates of eGFR slopes
that are steeper (more negative) than one would expect for
patients without hypertension.
In conclusion, we found diabetes to be the strongest pre-
dictor of both incident CKD and eGFR decline in a diverse
cohort of hypertensive patients from an inner-city, integrat-
ed delivery system. In addition, we found no difference by
race/ethnicity in rates of incident CKD or in decline of kid-
ney function. The presence of vascular disease at baseline
in patients with diabetes was additive. Our findings sug-
gest that efforts to prevent the development of CKD should
focus on awareness of risk factors for diabetes and vascular
disease. Further work on preventing the development of
and slowing the progression of kidney disease in hyperten-
sive patients is necessary.
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Abstract
Background. We retrospectively reviewed the medical re-
cords of all patients who underwent surgery as part of the
treatment of renovascular hypertension (RVH) at our centre
between 1979 and 2008.
Patients. Thirty-seven children (65% male) with a median
age of 7.6 (0.4–17.9) years were identified with a median
systolic blood pressure (SBP) of 140 (105–300) mm Hg
prior to surgery. Bilateral renal artery stenosis and intra-re-
nal disease were present in 19 (51%) patients, mid-aortic
syndrome in 15 (40%), involvement of visceral arteries in
eight out of 35 (23%) and coexisting cerebral disease in
eight out of 30 (26%) investigated patients.
Results. Surgical procedures (n = 53) included (i) nephrec-
tomy (18, of which two unplanned and two secondary due
to technical failure), (ii) renovascular surgery on the renal
arteries (28, of which 18 had autologous surgery and 10
synthetic grafts inserted for revascularisation) and (iii) aor-
tic reconstruction with (6) and without (1) a synthetic
graft. Post-operative complications were haemorrhage
(5), septicaemia (5) and chylous ascites (1). There were
no perioperative deaths; two children died during follow-
up. The SBP post-surgery improved to a median value of
116 (range 90–160) mm Hg. Twelve months after surgery,
16 (43%) children had normal blood pressure without
treatment, 15 (41%) normal or improved on one to four
antihypertensive drugs and four (11%) unchanged; no data
were available for two (5%) children.
Conclusion. Surgery effectively treated the hypertension
of 90% of our children, when performed in conjunction
with medical therapy and interventional radiology. In spite
of aggressive surgical treatment, RVH is sometimes a pro-
gressive disease.
Keywords: bypass; children; graft; nephrectomy; renovascular
hypertension
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